image
Healthcare - Biotechnology - NASDAQ - DK
$ 152.695
-1.28 %
$ 9.14 B
Market Cap
-21.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ASND stock under the worst case scenario is HIDDEN Compared to the current market price of 153 USD, Ascendis Pharma A/S is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ASND stock under the base case scenario is HIDDEN Compared to the current market price of 153 USD, Ascendis Pharma A/S is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ASND stock under the best case scenario is HIDDEN Compared to the current market price of 153 USD, Ascendis Pharma A/S is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ASND

image
$170.0$170.0$165.0$165.0$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
364 M REVENUE
36.34%
-279 M OPERATING INCOME
38.81%
-378 M NET INCOME
21.47%
-306 M OPERATING CASH FLOW
34.48%
6.88 M INVESTING CASH FLOW
-97.60%
444 M FINANCING CASH FLOW
230.57%
174 M REVENUE
200.72%
383 K OPERATING INCOME
100.40%
-38.5 M NET INCOME
64.83%
-87.2 M OPERATING CASH FLOW
-42.19%
-384 K INVESTING CASH FLOW
-63.16%
87 K FINANCING CASH FLOW
103.54%
Balance Sheet Ascendis Pharma A/S
image
Current Assets 1.06 B
Cash & Short-Term Investments 560 M
Receivables 177 M
Other Current Assets 324 M
Non-Current Assets 119 M
Long-Term Investments 13.6 M
PP&E 98.7 M
Other Non-Current Assets 6.34 M
47.44 %15.04 %27.46 %8.37 %Total Assets$1.2b
Current Liabilities 908 M
Accounts Payable 96.4 M
Short-Term Debt 492 M
Other Current Liabilities 320 M
Non-Current Liabilities 377 M
Long-Term Debt 365 M
Other Non-Current Liabilities 12.3 M
7.50 %38.25 %24.89 %28.41 %Total Liabilities$1.3b
EFFICIENCY
Earnings Waterfall Ascendis Pharma A/S
image
Revenue 364 M
Cost Of Revenue 44.3 M
Gross Profit 319 M
Operating Expenses 598 M
Operating Income -279 M
Other Expenses 99.3 M
Net Income -378 M
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)364m(44m)319m(598m)(279m)(99m)(378m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
87.83% GROSS MARGIN
87.83%
-76.66% OPERATING MARGIN
-76.66%
-103.97% NET MARGIN
-103.97%
357.68% ROE
357.68%
-32.05% ROA
-32.05%
-37.00% ROIC
-37.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ascendis Pharma A/S
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -378 M
Depreciation & Amortization 17.7 M
Capital Expenditures -1.43 M
Stock-Based Compensation 95.5 M
Change in Working Capital -107 M
Others 159 M
Free Cash Flow -308 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ascendis Pharma A/S
image
Wall Street analysts predict an average 1-year price target for ASND of $195 , with forecasts ranging from a low of $140 to a high of $289 .
ASND Lowest Price Target Wall Street Target
140 USD -8.31%
ASND Average Price Target Wall Street Target
195 USD 27.50%
ASND Highest Price Target Wall Street Target
289 USD 89.27%
Price
Max Price Target
Min Price Target
Average Price Target
300300280280260260240240220220200200180180160160140140120120100100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Ascendis Pharma A/S
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock? Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. zacks.com - 2 weeks ago
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. globenewswire.com - 1 month ago
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros. benzinga.com - 1 month ago
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call. seekingalpha.com - 1 month ago
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs – Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares globenewswire.com - 1 month ago
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results – Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million globenewswire.com - 1 month ago
Ascendant Resources Announces Closing of First Tranche of Private Placement • Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / February 11, 2025 / Ascendant Resources Inc. (TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche(TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche") of the private placement (the "Placement") previously announced on February 3, 2025 in connection with the arrangement agreement (the "Arrangement Agreement") it entered into with Cerrado Gold Inc. ("Cerrado"), whereby Cerrado has agreed to acquire all of the issued and outstanding common shares of Ascendant (each an "Ascendant Share") by way of a plan of arrangement (the "Arrangement"). Under the First Tranche, the Company has issued 45,047,617 Ascendant Shares at the price of C$0.0525 per Ascendant Share for gross proceeds of approximately C$2.365 million through a combination of cash and the satisfaction of outstanding debt. accessnewswire.com - 1 month ago
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. globenewswire.com - 1 month ago
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade) TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options. seekingalpha.com - 2 months ago
Ascendis Pharma: Danish Blockbuster Hunter Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential. Ascendis' diverse pipeline supports a positive investment thesis, suggesting significant future advancements and market opportunities. seekingalpha.com - 2 months ago
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference - Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P. globenewswire.com - 2 months ago
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California. globenewswire.com - 2 months ago
8. Profile Summary

Ascendis Pharma A/S ASND

image
COUNTRY DK
INDUSTRY Biotechnology
MARKET CAP $ 9.14 B
Dividend Yield 0.00%
Description Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Contact Tuborg Boulevard 12, Hellerup, 2900 https://ascendispharma.com
IPO Date Jan. 28, 2015
Employees 1017
Officers Dr. Stina Singel M.D., Ph.D. Executive Vice President & Head of Clinical Development for Oncology Mr. Scott T. Smith Chief Financial Officer, Executive Vice President & Member of Executive Board Mr. Michael Wolff Jensen L.L.M. Executive Vice President, Chief Legal Officer & Member of the Executive Board Mr. Flemming Steen Jensen Executive Vice President of Product Supply & Quality Mr. Joseph Kelly Head of U.S. Commercial of Endocrinology Mr. Jan Moller Mikkelsen President, Chief Executive Officer, Member of Executive Board & Executive Director Mr. Mads Bodenhoff Senior Vice President, Head of Finance & Principal Accounting Officer Dr. Kennett Sprogoe Ph.D. Executive Vice President and Head of Research & Product Development Mr. Timothy J. Lee Senior Director of Investor Relations Ms. Lotte Sonderbjerg Executive Vice President, Chief Administrative Officer & Member of the Executive Board